Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.64 |
| ▸ | BRD2 | P25440 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | TSPO | P30536 | 1/20 | 0.57 |
| ▸ | EP300 | Q09472 | 1/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652816 | 0.85 | BRD4 (0.68) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL21652825 | 0.84 | BRD4 (0.67) | BRD4 | |
| SCHEMBL20384191 | 0.83 | BRD4 (0.75) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23436757 | 0.82 | BRD4 (0.63) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL23403827 | 0.81 | BRD4 (0.44) | BRD4BRD2BRD3BRDT | |
| SCHEMBL21652741 | 0.80 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15067602 | 0.78 | BRD4 (1.00) | BRD4BRD2BRD3BRDT | |
| SCHEMBL20384342 | 0.78 | BRD4 (0.72) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL21652790 | 0.78 | BRD4 (0.40) | BRD4BRD2BRD3BRDT | |
| SCHEMBL23436641 | 0.77 | BRD4 (0.76) | BRD4BRD2ADORA2BTSPOEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-09-30 | — | — | US | disclosed |
| WO-2021143922-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | 正大天晴药业集团股份有限公司 | 2021-07-22 | — | — | WO | disclosed |
| EP-3828183-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828183-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020020288-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300923-A1 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | BRD1, BRD4, BRD2 | BRD4 2/4885BRD2 3/4885ADORA2B 4499/4885 |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | BRD4 1/4885BRD2 5/4885ADORA2B 4616/4885 |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | BET1, BRD7, BRWD1 | BRD4 9/4885BRD2 19/4885ADORA2B 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.